Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at Maxim Group

Maxim Group initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report sent to investors on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $5.00 price target on the biopharmaceutical company’s stock.

Separately, Wall Street Zen initiated coverage on shares of Akari Therapeutics in a research note on Wednesday, May 21st. They issued a “sell” rating for the company.

Akari Therapeutics Stock Performance

Shares of NASDAQ:AKTX opened at $1.13 on Friday. Akari Therapeutics has a 1 year low of $0.85 and a 1 year high of $4.40. The business has a fifty day simple moving average of $1.22 and a 200 day simple moving average of $1.20.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.